Immunome Inc (NASDAQ:IMNM) price on Thursday, April 10, fall -0.16% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.20.
A look at the stock’s price movement, the close in the last trading session was $6.21, moving within a range at $5.76 and $6.3. The beta value (5-Year monthly) was 2.059. Turning to its 52-week performance, $21.72 and $5.15 were the 52-week high and 52-week low respectively. Overall, IMNM moved -32.68% over the past month.
Immunome Inc’s market cap currently stands at around $539.09 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-18.
The average forecast suggests down to a -55.57% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.94M, representing a -78.53% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IMNM is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend IMNM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IMNM’s current price about -13.75% and -29.77% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.76, while 7-day volatility ratio is 13.98% and 9.14% in the 30-day chart. Further, Immunome Inc (IMNM) has a beta value of 2.07, and an average true range (ATR) of 0.68. Analysts have given the company’s stock an average 52-week price target of $33, forecast between a low of $23 and high of $35. Looking at the price targets, the low is -270.97% off current price level while to achieve the yearly target high, price needs to move -464.52%. Nonetheless, investors will most likely welcome a -432.26% jump to $33 which is the analysts’ median price.
If we refocus on Immunome Inc (NASDAQ:IMNM), historical trading data shows that trading volumes averaged 1.74 over the past 10 days and 1.13 million over the past 3 months. The company’s latest data on shares outstanding shows there are 86.95 million shares.
The 13.27% of Immunome Inc’s shares are in the hands of company insiders while institutional holders own 61.48% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 9.52 million on 2025-03-14, giving us a short ratio of 13.83. The data shows that as of 2025-03-14 short interest in Immunome Inc (IMNM) stood at 1138.00004 of shares outstanding, with shares short rising to 9.35 million registered in 2025-02-14. Current price change has pushed the stock -41.62% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IMNM stock continues to rise going into the next quarter.
